证券日报网讯12月19日，海正药业（600267）在互动平台回答投资者提问时表示，公司严格按照相关法 律法规要求做好信息披露工作，不存在应披露未披露事项。公司始终秉持尊重与坦诚的态度，重视与广 大投资者的沟通，过去几年公司每年均与百余家机构投资者交流，今年以来已累计接待或反路演包括博 时、交银、汇添富、睿远、人保、广发等150余家调研交流。公司相信只要把基本面做好，通过战略布 局提速和市值管理配合，海正药业终会回归应有的市场价值。二级市场买卖交易系市场行为，请注意投 资风险，谨慎投资。 ...

证券日报网讯12月19日，海正药业（600267）在互动平台回答投资者提问时表示，公司发布回购股份方 案是基于对公司未来持续稳定发展的信心和对公司价值的高度认可，后续将根据回购方案及市场情况在 回购期限内择机实施回购，并及时履行信息披露义务。 ...

Group 1 - The company has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), classified as a Category V new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The new drug is developed by Zhejiang Haizheng Animal Health Products Co., Ltd. in collaboration with seven other companies, and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug is indicated for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation of the eyes/ears, among other steroid-responsive inflammatory/allergic diseases [1] Group 2 - The registration application for the new veterinary drug was submitted in October 2024, and the product is now ready for production and market launch pending the approval of the veterinary product number [1] - Currently, the company has not been able to obtain specific sales revenue data for similar products from other companies through public channels [2]

本报讯(记者袁传玺)天眼查App显示，近日，浙江凌愈制药有限公司成立，注册资本1亿元，经营范围包 括药品生产、药品批发、技术进出口、货物进出口等。股东信息显示，该公司由浙江圣兆药物科技股份 有限公司、海正药业（600267）共同持股。 ...

Core Viewpoint - Zhejiang Lingyu Pharmaceutical Co., Ltd. has been established with a registered capital of 100 million yuan, focusing on drug production, wholesale, and import-export activities [1] Company Summary - The legal representative of Zhejiang Lingyu Pharmaceutical Co., Ltd. is Zhang Hongyao [1] - The company is co-owned by Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. and Haizheng Pharmaceutical (stock code: 600267) [1] Industry Summary - The establishment of Zhejiang Lingyu Pharmaceutical indicates ongoing investment and development in the pharmaceutical sector, particularly in drug production and distribution [1]

Core Viewpoint - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has received a new veterinary drug registration certificate for its product, Methylprednisolone Tablets (for dogs), which is classified as a Category V new veterinary drug, indicating compliance with relevant regulations and enhancing the company's strategic positioning in the veterinary medicine sector [1][4]. Group 1: New Veterinary Drug Information - The new veterinary drug is named Methylprednisolone Tablets (for dogs) and has been approved as a Category V new veterinary drug [1]. - The registration certificate number for the new veterinary drug is (2025) New Veterinary Drug Certificate No. 129 [1]. - The drug is developed by Zhejiang Hai Zheng Animal Health Products Co., Ltd. in collaboration with seven other companies [1]. Group 2: Drug Application and Use - Methylprednisolone Tablets (for dogs) are intended for the treatment of canine inflammatory and allergic diseases, and can be part of treatment regimens for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation of the eyes/ears [1]. - The drug is effective for various inflammatory/allergic diseases that can be treated with glucocorticoids, including immune-mediated diseases [1]. Group 3: Market Position and Future Outlook - The approval of Methylprednisolone Tablets (for dogs) is expected to enhance the company's market competitiveness in the veterinary drug sector [4]. - The product is now ready for production and market launch, pending the acquisition of the veterinary product approval number, although it is noted that it will not have a significant short-term impact on the company's performance [4].

Company Announcements - Guo Xin Technology's former actual controller Chen Chongjun was sentenced to six years in prison and fined 4 million yuan for manipulating the securities market [2] - Zhongwei Company is planning to acquire the controlling stake in Hangzhou Zhonggui, leading to a stock suspension [3] - Xusheng Group's controlling shareholder is planning a change of control, resulting in a stock suspension [4] - Yidong Electronics' major shareholders reduced their holdings by 2.3463 million shares between December 10 and December 17 [5] - Nandu Power's controlling shareholder has terminated plans for a change of control, leading to stock resumption [6] - Xibu Mining's subsidiary obtained a mining license for a site with 2.86 tons of gold metal [8] Financial Adjustments - Shandong Highway plans to provision for a long-term equity investment impairment of approximately 690 million yuan related to Dongxing Securities [8] - WuXi AppTec's third and fourth largest shareholders reduced their holdings by a total of 29.508 million shares between November 26 and December 17 [9] Investments and Partnerships - Weixinno plans to sign an investment cooperation agreement to advance the Hefei 8.6 generation AMOLED production line project with a capital of 9.443 billion yuan [10] - Jiangnan New Materials is investing 300 million yuan to build a high-end copper-based core material R&D and industrialization project [15] Shareholding Changes - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [11] - Lidasin's fifth largest shareholder reduced their holdings by 1.56% between December 10 and December 17 [12] - Ruicheng Environmental Protection's shareholder plans to reduce their holdings by up to 3% [17] Dividends and Profit Distribution - Haitian Flavoring plans to maintain a cash dividend ratio of no less than 80% for the next three years (2025-2027) [13] - CICC announced a cash dividend distribution of 434 million yuan for the first half of 2025, with a record date of December 26 [14] Financing and Listings - Baipusais plans to issue H-shares and list on the Hong Kong Stock Exchange [21]

浙江海正药业股份有限公司 关于子公司获得新兽药注册证书的公告 证券代码：600267 证券简称：海正药业 公告编号：临 2025-80 号 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海 正动物保健品有限公司（以下简称"海正动保公司"）收到中华人民共和国农业 农村部核准签发的甲泼尼龙片（犬用）《新兽药注册证书》，该新兽药产品正式 获批五类新兽药。现就相关情况公告如下： 一、新兽药的基本情况 2024 年 10 月，中华人民共和国农业农村部受理了海正动保公司与其他单位 联合递交的甲泼尼龙片（犬用）的新兽药注册申请。 截至目前，公司通过公开渠道未能获得市场其他公司上述同类产品具体销售 收入数据。 三、风险提示 本次海正动保公司甲泼尼龙片（犬用）产品获得五类《新兽药注册证书》， 标志着上述产品已符合《兽药管理条例》和《兽药注册办法》相关规定，有利于 进一步推动公司在兽药板块的战略布局，提升公司市场竞争力。目前上述产品具 备生产和上市条件，待取得兽药产品批准文号后上市 ...

海正药业（600267）(600267.SH)发布公告，近日，公司控股子公司浙江海正动物保健品有限公司(简 称"海正动保公司")收到中华人民共和国农业农村部核准签发的甲泼尼龙片(犬用)《新兽药注册证书》， 该新兽药产品正式获批五类新兽药。 本次海正动保公司甲泼尼龙片(犬用)产品获得五类《新兽药注册证书》，标志着上述产品已符合《兽药 管理条例》和《兽药注册办法》相关规定，有利于进一步推动公司在兽药板块的战略布局，提升公司市 场竞争力。 ...

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Methylprednisolone Tablets (for dogs), officially classified as a Category 5 new veterinary drug [1] Group 1 - The new veterinary drug, Methylprednisolone Tablets (for dogs), is developed in collaboration with six other companies and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug can be used as part of treatment regimens for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation in the eyes/ears, as well as other inflammatory/allergic diseases effectively treated with glucocorticoids, including immune-mediated diseases [1]